Electronic Pregnancy Prevention Programme portal (ePPP) now available for lenalidomide and thalidomide
Visit the Portal (ePPP) page to learn more and request a demonstration
Lenalidomide Accord
Multiple myeloma
Lenalidomide Accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.
Lenalidomide Accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2 of the SmPC) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
Lenalidomide Accord in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Lenalidomide Accord as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
Mantle cell lymphoma
Lenalidomide Accord as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1 of the SmPC)
Follicular lymphoma
Lenalidomide Accord in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).
Thalidomide
Thalidomide capsules in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy.
Thalidomide capsules are prescribed and dispensed according to the Thalidomide Pregnancy Prevention Programme (see section 4.4 of the SmPC)
Please refer to the SmPC and Accord lenalidomide and/or thalidomide Healthcare Professional Brochure before prescribing
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Accord-UK Ltd on 01271 385257 or email [email protected].
